Corporate information

Registration country

Company type

Cancer drug development company.

Funding rounds

Acquisition USD 10,200,000,000


USD 10,200,000,000 ( ) at USD 10,200,000,000 pre-money valuation
The deal includes USD5.8 billion in upfront payments, includingUSD2 billion in stock, as well as USD4 billion in cash-based earnouts, plus a return to shareholders of Stemcentrx of cash on hand.

Profile Country Notes
Abbie Inc USD 10,200,000,000 (USD 10,200,000,000)

Series G USD 250,000,000


USD 250,000,000 ( )

Profile Country
Artis Ventures Venture capital firm

Series F USD 200,000,000


USD 200,000,000 ( )

Profile Country
Artis Ventures Venture capital firm

Series C USD 23,530,000


USD 23,530,000 ( )

Profile Country Notes
Artis Ventures Venture capital firm (Led the round.)

Profile Country Notes
OakHouse Partners Initial investment. (via Alpha Fund) Exited. (Trade sale)


Investment activity status
Not investing

Current team

Current team

Financials